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Résumé: La dépression majeure peut être très dommageable pour le 8% des Nord-Américains 
qui en souffriront au moins une fois durant leur vie. Les traitements actuels de la dépression 
ont été créés grâce à la compréhension de l'hypothèse de la monoamine; où les transporteurs 
de la sérotonine ou les enzymes sont bloqués ou inhibés afin de maintenir le neurotransmetteur 
(NT) dans la fente synaptique. Sur une période de plusieurs semaines, cette augmentation de 
NT encourage la plasticité synaptique, ce qui augmente la sensibilité de réponse de 5-HT dans 
la fente synaptique. Cette forme de traitement est efficace chez 40% des patients, tandis que 
les 60% restants ont une réponse partielle ou  nulle. Dans les modèles de dépression chez la 
souris des changements dans les niveaux de phosphorylation de CREB sont corrélés aux effets 
antidépresseurs (AD). Dans le cas RS67333, des effets AD apparaissent après 2 à 3 jours de 
traitement. Les effets anti-anhédoniques sont démontrés par la réponse au traitement. RS67333 
est un agoniste spécifique du récepteur 5-HT4, un récepteur couplé à la protéine G (GPCR) qui 
est généralement situé, après synapses, dans les régions du système limbique. Il existe d'autres 
ligands qui sont également spécifiques au récepteur 5-HT4: 5-HT, Zacopride, Prucalopride et 
ML10302, mais les mêmes effets anti-anhédoniques constatés lors de RS67333 n’ont pas été 
observés. Comment RS67333 est-il différent des autres en termes de signalisation? Nous 
avons utilisé le transfert d’énergie par résonnance de bioluminescence (BRET) pour étudier les 
interactions 5-HT4R avec les sous-unités, α β γ de la protéine G et nous avons comparé ces 
associations avec d'autres agonistes connus de 5-HT4. Nous avons constaté que RS67333 est 
un agoniste partiel et qu’il active un changement conformationnel de la protéine Gαs, mais 
n’active pas un changement conformationnel de la protéine Gαo. Prucaloride, 5-HT et 
Zacopride induisent aussi un changement de conformation du complexe Gαs, mais pas 
ML10302. Pour la formation de Gαo, Prucalopride, ML10302 et 5-HT agissent comme des 
agonistes, mais pas zacopride ni RS67333. Nous avons utilisé un test de dosage immuno-
enzymatique sur support solide (ELISA) pour mesurer l’intériorisation induite par les ligands 
pour étudier la régulation des récepteurs. Nous avons constaté que RS67333 et ML10302 
n’induisent pas l'internalisation du récepteur, tandis que zacopride, prucalopride et 5-HT sont 
très efficaces. L'efficacité sous-optimale des ADs actuels met l’accent sur la nécessité de 
développer des médicaments avec d'autres mécanismes d'action. RS67333 a des effets 
persistants anti-anhédoniques après une courte période de temps, et d'autres études de ses 
propriétés de signalisation pourraient donner lieu à une nouvelle génération d’antidépresseurs 
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rapides de longue durée d’action. 
Mots-clés: 5-HT, RS 67333, BRET, AD, antidépresseur, CREB, anhédonie, zacopride, 
prucalopride, ML 10302, GPCR, récepteur 5-HT4, sélectivité fonctionnelle.  
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Abstract: Major Depression can be very damaging on the 8% of North Americans that will 
have it at least once within their lifetime. Current treatments of depression have been 
developed through the understanding of the monoamine hypothesis; whereby serotonin (5-HT) 
transporters or enzymes are blocked or inhibited in order to maintain the neurotransmitter in 
the synaptic cleft. Over a period of several weeks this increase in NT induces synaptic 
plasticity which increases the response sensitivity of 5-HT in the synaptic cleft. This form of 
treatment is effective on 40% of patients, while the remaining 60% have partial or no 
response. In mouse models of depression, changes in phosphorylation levels of CREB 
correlated to antidepressants (AD) effects. In the case of RS67333 AD effects appear within 2-
3 days of treatment. The response can be evidenced as anti- anhedonic. RS67333 is specific 
agonist for 5-HT4 receptor, a G protein coupled receptor (GPCR) that is typically located post 
synaptically, in limbic regions. There are other ligands that are also specific to receptor 5-HT4: 
5-HT, Zacopride, prucalopride and ML10302, but have not been observed to have the same 
anti-anhedonia effects of RS67333. How does RS67333 differ from the others in terms of 
signaling? We used bioluminescence resonance energy transfer (BRET) to study the 
interactions of 5-HT4R with the α β γ subunits of the G protein and we compared these 
associations with other known 5-HT4 agonists. We found that RS67333 was a partial agonist 
and activated a conformational change of the Gαs protein but did not activate a conformational 
change of Gαo protein. Prucaloride, 5-HT and Zacopride also induced a conformational change 
of the Gαs complex but not ML10302. For the formation of Gαo, Prucalorpide, ML10302 and 
5-HT acted as agonists, but not Zacopride. We used an ELISA assay to measure ligand 
induced internalization to study receptor regulation. We found that RS67333 and ML10302 
did not induce receptor internalization, while Zacopride, Prucalopride and 5-HT  were very 
effective. The suboptimal efficacy of current ADs stresses the need to develop drugs with 
other mechanisms of action. RS67333 has persistent anti-anhedonia effects after a short period 
of time and further studies of its signalling properties may open up a new generation of fast 
and long acting antidepressants. 
Keywords: 5-HT, RS67333, BRET, AD, antidepressant, pCREB, anhedonia, Zacopride, 
prucalopride, ML10302, GPCR, 5-HT4  receptor, functional selectivity. 
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Introduction 
1. Socio-economics of depression 
The World Health Organization (WHO) has estimated that Major Depressive Disorder (MDD) 
will be the leading cause of disability by the year 2030 (WHO 2016). If true, this will have 
major impacts on the delivery of heath care services, and even the economy as a whole. 
Already mental disorders are the greatest cause of severe functional impairment (42%) 
compared to chronic physical disorders (24%)(Druss, Hwang et al. 2009). Mental disorders 
also have lower rates of treatment success (21.4%) compared to chronic physical disorders 
(58.2%). A further consideration is that physical disorders affect work or home functions, 
whereas mental disorders are commonly most disruptive to social interactions and close 
relationships. A depressed individual has a greater need of social support, but tragically, 
instead of fostering support, mental disorders  often disrupt family stability and contribute to 
the breakdown of relationships, including causing separation or divorce (WHO 2016).  
A 5 year study of 2334 participants over 5 years with an annual family income greater than 
$25,000 USD found that 33% of families with a depressed individual had a family member 
become newly unemployed compared to 21% of non-depressed families (Whooley, Kiefe et 
al. 2002). After correcting for confounding factors the association remained highly significant 
at 17% for depressed families and 7% for non-depressed. The remaining depressed employees 
that manage to keep their jobs on average lose an estimated 27 days of a year or 
~$4400/individual and $36.6 billion dollars US on account of absenteeism and presenteeism 
(Broadhead, Blazer et al. 1990; Kessler, Merikangas et al. 2008). (Absenteeism is missed work 
days whereas presenteeism is being present at work, but with a significant decrease in 
productivity.) 
2. Symptoms 
MDD is a disease of mental health that’s characterized by a persistent low mood, low self-
esteem. The primary symptom of MDD is anhedonia: a lack of the capacity to experience 
pleasure. Sufferers of depression feel sadness, emptiness, experience excessive feelings of 
guilt and/or have suicidal thoughts that may be acted on. It affects women more than men and 
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most often occurs in the fourth decade of life (Kessler, Merikangas et al. 2008). A major 
depressive episode can be triggered by a variety of factors such as chronic stress, isolation, 
family loss, failing a class, physical or emotional abuse, or job loss. These episodes typically 
average 6 months during the otherwise active years of an adult life, resulting in less effective 
work and more days off. Depression is a burden on the person, the family, the work, and the 
economy. Those that have suffered already one episode of depression have increased risk of 
suffering again (Burcusa and Iacono 2007). 
To make matters worse, depressed individuals are twice as likely to die from other causes 
(1.9x for men and 2.1x for women)(Osby, Brandt et al. 2001). These include having twice the 
risk of coronary heart disease, increased risk of cardiovascular death and stroke (Barth, 
Schumacher et al. 2004). Depressed men are 21 times more likely to commit suicide than there 
non-depressed counterparts, while depressed woman are 27x more likely to do so (Osby, 
Brandt et al. 2001). There are 120 million persons with MDD worldwide (WHO 2016) and 
depression has a recurrence of 85% over 15 years (ten Doesschate, Bockting et al. 2010). 
2.1. Current Treatments 
MDD is currently resistant to treatment, and remission is rarely accompanied by a total 
disappearance of all symptoms. In general, cognitive impairment and social dysfunction still 
persist despite treatment with anti-depressants (AD) . The lack of success through AD 
treatment can be attributed to a lack of progress in the identification of pharmacological 
targets. Today’s AD targets are similar to those of 50 years ago. Almost all AD drugs act 
through the serotonergic and/or noradrenergic neurotransmitter systems, and more recently, 
the dopaminergic system. Treatment efficacy only improves depressive symptoms on two-
thirds of those diagnosed with MDD (Nelson 1999). Even if effective, current AD drugs take 
3-4 weeks before clinical efficacy can be observed. Nestler and others have postulated that the 
lag period for their clinical effects is due to the longer time necessary for lasting neuroplastic 
changes in selective brain regions (Nestler, Barrot et al. 2002).  
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3. Depression hypotheses 
3.1. Monoamine Hypothesis 
The mechanisms of depression are not fully understood, and one prominent hypothesis is 
that it is caused by a monoamine deficiency in the brain. This hypothesis was developed 
by Schildkraut, following the work by Selikoff and Robitzek (Crane 1956)  with the drug 
iproniazid  on tuberculosis patient when they found that their patients were “dancing in the  
Figure 1. The normal processes of 5-HT 
and noradrenaline neurotransmission. 
When a nerve impulse arrives at a 5-HT or 
noradrenaline nerve terminal the neurotransmitter 
is released from the synaptic vesicle into the 
synaptic cleft. Neurotransmitter molecules bind to 
their specific receptors on the post-synaptic 
membrane and the nerve impulse is propagated or 
inhibited, depending on the receptor type. 5-HT 
and noradrenaline molecules are then released from 
their receptors and taken back into the nerve 
terminal via either the 5-HT or noradrenaline re-
uptake transporters. 5-HT and noradrenaline are 
degraded by monamine oxidase and catechol-O-
methyl transferase, these enzymes are found in 
both the synaptic cleft and in the nerve terminal. 
(Rang HP 2001). 
 
halls tho’ there were holes in their lungs” following several months of treatment with the drug 
(Schildkraut 1965; Sandler 1990; López-Muñoz, Alamo et al. 1998). The monoamine 
hypothesis was put forward some 50 years ago and proposes that the underlying 
neuroanatomical basis for depression is the deficiency of central noradrenergic and/or 
serotonergic systems (Figure 1) (Schildkraut 1965). Targeting these systems had a tendency in 
some cases to restore normal function to otherwise depressed patients (Lopes Rocha, 
Fuzikawa et al. 2013). While an increase in monoamines is rapidly observed following an 
acute AD treatment, symptoms only appear to be eliminated after 2 to 4 weeks of chronic 
treatment (French, Krauss et al. 2013).  The Monoamine hypothesis does not provide an 
adequate explanation for this latency nor does it explain the pathophysiology of depression. 
This understanding of depression implies a simple explanation for MDD despite the brain’s 
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complicated machinery, describing MDD as the result of an ‘imbalance. But there is a chasm 
of understanding between treatment and clinical efficacy, yet drugs have been developed only 
addressing this initial step. They’ve been developed to increase serotonin in the synaptic gap 
through methods of blocking reuptake receptors or degradation machinery. These drugs fail to 
reconcile the objective of increased serotonin in this gap or account for the variety of systems 
in the brain and how they are affected and how it alleviates symptoms of depression.  Drugs 
developed based solely on the monoamine hypothesis do not adequately treat depression 
(Belmaker and Agam 2008).  
3.2. Neurotrophic hypothesis 
More recently, there has been mounting evidence that depression is a result of a dysregulation 
of neurogenesis (Massart, Mongeau et al. 2012). In a depressed patient, there is a reduction of 
hippocampus size and these patients show greater activity in the atrophy of neurons 
(Sivakumar, Kalmady et al. 2015). Research into animal models of depression, as well as 
human patients treated with ADs, began to exhibit AD effects and had increased neurogenesis 
in specific regions of the brain (Duman and Monteggia 2006; Krishnan and Nestler 2008; 
Castrén and Rantamäki 2010). In the areas of the brain specific to behaviour, such as the 
prefrontal cortex, and the hippocampus (Duman, Heninger et al. 1997). AD treatment has been 
shown to promote neurogenesis and synaptogenesis in these systems (Czeh and Di Benedetto 
2013). Serotonin level is positively correlated with hippocampal neurogenesis (Brezun and 
Daszuta 2000; Banasr, Hery et al. 2004) and the stimulation of several serotonergic receptors 
(Radley and Jacobs 2002; Lucas, Rymar et al. 2007). These increases are crucial for the 
proliferation, differentiation and survival of new hippocampal neurons (Brezun and Daszuta 
2000; Kulkarni, Jha et al. 2002; Santarelli, Saxe et al. 2003; Banasr, Hery et al. 2004; Banasr, 
Soumier et al. 2006; Lucas, Rymar et al. 2007).  
3.3. New Pathophysiology 
Research efforts have tried to identify molecules and pathways that might be relevant to 
synaptic plasticity. Several secondary, tertiary, and quaternary messenger cascades have been 
postulated to occur in response to AD therapy. Neurotrophic factors such as Brain Derived 
Neutrophic Factor (BDNF) have been found to be essential in these cascades (Figure 2). 
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Antidepressant treatment increases the expression of BDNF in the Hippocampus and 
Prefrontal cortex (Drevets, Price et al. 2008; MacQueen, Yucel et al. 2008). Exposure to 
repeated stress causes atrophy of neurons in the hippocampus and prefrontal cortex as well as 
a loss of glia, necessary for the maintenance and supply of nutrients and oxygen to the neurons 
(Ogundele, Omoaghe et al. 2014). BDNF is primarily under the control of cyclic Adenine 
monophosphate (cAMP) Response Element (CRE), suggesting a putative role for the 
transcription factor CREB as the source of BDNF’s activity-dependent effects. Serotonin 
receptors (5-HTR) are G protein coupled receptors (GPCR) and some of which act directly on 
cAMP production in the hippocampus and prefrontal cortex.  Thus, targeting 5-HTRs that 
have specific pathway in certain regions of the brain may be a more effective in the treatment 
of MDD. 
3.4. 5-HTR G-protein coupled receptors 
There are 14 receptors specific for serotonin (Palacios 2015). They are labeled 5-HT1 to 5-HT7 
and have as many as five isoforms. Receptor 5-HT1 has five isoforms  that vary in abundance 
 
Figure 2. Activity-dependent BDNF hypothesis of depression.  
Increased neuronal activity, induced by an enriched environment (e.g., physical exercise, mental stimulation 
with learning exercise and sensory input, and social interactions) and/or medication up-regulates BDNF 
expression in the hippocampus and cortex. This, in turn, increases neuronal activity and this positive 
feedback loop can maintain an active mind state. In contrast, any disruption in BDNF expression, caused by 
epigenetic regulation processes, stress, and/or reduced neuronal activity, would lead to decreases in neuronal 
activity and activity-driven BDNF expression. This vicious cycle of decreased neuronal activity and reduced 
BDNF expression may cause depression (Sakata 2014) 
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and activity all over the body.  The receptor 5-HT1A is an isoform that has been implicated in 
the modulation of mood and anxiety related behaviours. 5-HT1a knock out mice are insensitive 
to the behavioural effects of chronic fluoxetine suggesting that activation of 5-HT1a receptors 
is also a critical component in the mechanism of  Selective Serotonin Reuptake Inhibitors 
(SSRI) (Figure 3) (Santarelli, Saxe et al. 2003).  The 5-HT1B  receptor’s function  varies in 
function  depending on its location. In the frontal cortex it will act as a postsynaptic receptor, 
inhibiting the release of dopamine.  But in the striatum and basal ganglia, it functions as an 
autoreceptor inhibiting the release of serotonin (Breuer, Groenink et al. 2007). 5-HT1D 
receptors act as autoreceptors in the dorsal raphe nuclei, but are also found in the heart where 
they modulate the release of serotonin (van der Stelt, Breuer et al. 2005). In the Central 
Nervous System (CNS), 5-HT1D receptors are involved in locomotion and anxiety (Breuer, 
Groenink et al. 2007).   The function of the 5-HT1E receptors is unknown due to lack of 
selective pharmacological tools and permissive animal models.  It is hypothesized that the 5-
HT1E  is involved  in the regulation of memory due to its high abundance in the frontal cortex 
and hippocampus as well as its high degree of conservative genetic sequence (Chambliss, Van 
Hoomissen et al. 2004; Breuer, Groenink et al. 2007).  5-HT1F receptor distribution in the 
brain appears to be limited but detected in the uterus and in coronary arteries suggesting a 
possible role in vascular contraction (Pierce and Lefkowitz 2001) and has been targeted in the 
treatment of migraines (Neitzel 2010). With the exception of 5-HT3 receptor that 
homopenteramizes to form a ligand gated ion channel (Niesler 2011), all 5-HTRs are GPCR  
that activate intracellular secondary messengers which cascade to produce an excitatory or 
inhibitory response (Qi, Xia et al. 2014).  
 
4. 5-HT4 receptors 
4.1. Location and agonists 
5-HT 4 receptors are located in the heart, alimentary tract, adrenal and in the central nervous 
system structures such as the putamen, caudate nucleus, nucleus accumbens and substantia 
nigra (Figure 4). They are post synaptic receptors with growing evidence that activation of 5-
HT4 receptors is necessary for the treatment of depression (Mendez-David, David et al. 2014). 
There are already agonists on the market specific to this receptor (Zacopride and Prucalopride) 
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Figure 3. The mechanism of action of specific 5-HT re-uptake inhibitors. 
 The selective 5-HT re-uptake inhibitors (SSRIs) are thought to restore the levels of 5-HT in the synaptic cleft 
by binding at the 5-HT re-uptake transporter preventing the re-uptake and subsequent degradation of 5-HT. 
This re-uptake blockade leads to the accumulation of 5-HT in the synaptic cleft and the concentration of 5-HT 
returns to within the normal range. This action of SSRIs is thought to contribute to the alleviation of the 
symptoms of depression. In the presence of the SSRI, small amounts of 5-HT continue to be degraded in the 
synaptic cleft by monoamine oxidase and other machinery.(Rang HP 2001) 
and others currently under study (ML10302 and RS67333) (Lefebvre, Contesse et al. 1993; 
Briejer, Bosmans et al. 2001; Godínez-Chaparro, Barragán-Iglesias et al. 2011). Zacopride is 
primarily an anxiolytic but has antiemetic and pro-respiratory effects. Prucalopride is used for 
the treatment of impaired gastric motility. ML10302 is a partial agonist for receptor 5-HT4 that 
may have pro-nociceptive effects (Godínez-Chaparro, Barragán-Iglesias et al. 2011). RS67333 
is a partial agonist for receptor 5-HT4 and has been shown to have AD effects in mouse 
models of induced depression (Lucas, Rymar et al. 2007). These AD effects are observable 
after 2-3 days of treatment compared to the typical 3-4 week treatments needed of traditional 
ADs (Lucas, Rymar et al. 2007).  
4.2. 5-HT4R and depression research 
A recent study by Mendez et al. (2014) highlighted the importance of the 5-HT4 receptor in 
AD treatment (Mendez-David, David et al. 2014). Using a mouse model of depression induced 
through low doses of corticosteroids over the course of 4 weeks, a known means of inducing a 
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Figure 4.  Distribution of 5-HT4 receptors in the brain. 
The 5-HT4 receptor subtype is coupled to a G-protein that stimulates the intracellular messenger adenylate 
cyclase that, in turn, regulates neurotransmission. In the human brain, a high density of 5-HT4 receptors has 
been identified in the striato-nigral system, notably in the caudate nucleus, lenticular nucleus (putamen and 
globus pallidus) and the substantia nigra. Lower levels of expression of the 5-HT4 receptor have been shown in 
the hippocampus and the frontal cortex.(Waeber, Sebben et al. 1993; Domenech, Beleta et al. 1994; Reynolds, 
Mason et al. 1995) 
 
depressive/anxious state. The mice were then treated with fluoxetine and RS67333 as well as 
the 5-HT4 antagonist GR125487. The anxiolytic-like effect of fluoxetine and RS67333 was 
completely abolished by treatment with the antagonist GR125487. Without the 5-HT4 
antagonist GR125487, the anxiety phenotype that was induced was reversed by fluoxetine and 
RS67333. This emphasizes the importance of the 5-HT4 receptor for the treatment of 
depression.  The 5-HT4 receptor is important because its activation facilitates the maturation of 
newborn neurons in the adult hippocampus (Mendez-David, David et al. 2014). Chronic 
fluoxetine exposure resulted in an increase in the number of dividing neural precursors in the 
subgranular zone of the dentate gyrus (DG) (David, Samuels et al. 2009; Rainer, Xia et al. 
2012). RS67333 also increased the number of neural precursors in the subgranular zone, but to 
a lesser extent, 50% vs 170%. The antagonist GR125487 partially blocked this effect during 
fluoxetine exposure and completely blocked this effect with RS67333 exposure. A 7-day 
treatment of RS67333 produced anxiolytic and AD effects in many behavioural tests. The 
results suggest that the anxiolytic effect of RS67333 has a faster onset than fluoxetine and 
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Figure 5. G-protein-coupled receptor (GPCR)-mediated G-protein activation. 
 In the inactive state, G-proteins exist in the form of an αβγ heterotrimer, with the Gα subunit bound to GDP. 
Upon receptor activation, either by the binding of agonist or constitutively, the receptor changes to an active 
conformation (green), thereby activating G-proteins by promoting the exchange of GDP for GTP. The Gα-
GTP and Gβγ dimer functionally dissociate from one another and the receptor and are free to modulate 
downstream effectors. The cycle concludes when the GTPase activity of the Gα subunit hydrolyses GTP to 
GDP, allowing the Gα subunit to return to its resting confirmation and reassociate with Gβγ.(Smith, Sim‐
Selley et al. 2010) 
 
does not require hippocampal neurogenesis. Zacopride, Prucalopride, RS67333, and ML10302 
are all specific for the 5-HT4 receptor, but only RS67333 is functionally selective towards 
producing AD effects. How does the functional selectivity of RS67333 relate to the activation 
of the G proteins α, β and γ.  
 
5. G-Proteins 
5.1. G-proteins and GPCR 
G-proteins are specialized proteins with the ability to bind the nucleotide guanosine 
diphosphate (GDP) and guanosine triphosphate (GTP).  They consist of three subunits α, β, 
and γ. The α and γ subunits are attached to the plasma membrane by lipid anchors. The G 
protein α subunit will bind either GTP if active or GDP if inactive (Figure 5).  In the absence 
of a signal, GDP is attached to the α subunit and the G-protein-GDP complex binds to a 
nearby GPCR. Upon ligand activation, a change in the conformation of the GPCR activates 
the G protein and GTP physically replaces GDP bound to the α subunit. Binding of GTP to the 
α subunit dissociates the G protein into two parts: α bound to GTP and β-γ complex. These 
complexes are no longer bound to the GPCR, but remain bound to the lipid anchor. They are 
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Figure 6. Heterotrimeric G-protein activation in the context of GPCR signaling. 
Whenever a G protein is active, both its GTP-bound α subunit and its β-γ dimer can relay messages in the cell 
by interacting with other membrane proteins involved in signal transduction. Specific targets for activated G 
proteins include various enzymes that produce second messengers, as well as certain ion channels that allow 
ions to act as second messengers. Some G proteins stimulate the activity of these targets, whereas others are 
inhibitory. Vertebrate genomes contain multiple genes that encode the α, β, and γ subunits of G proteins. The 
many different subunits encoded by these genes combine in multiple ways to produce a diverse family of G 
proteins. In this diagram of G-protein-coupled receptor activation, the α, β, and γ subunits are shown with 
distinct relationships to the plasma membrane. After exchange of GDP with GTP on the α subunit, both the α 
subunit and the β-γ complex may interact with other molecules to promote signaling cascades. Note that both 
the α subunit and the β-γ complex remain tethered to the plasma membrane while they are activated. These 
activated subunits can act on ion channels in the cell membrane, as well as cellular enzymes and second 
messenger molecules that travel around the cell (Neitzel 2010).  
 
able to diffuse laterally to interact with other membrane proteins. The GTP bound α subunit 
remains active as long as GTP is bound. When GTP is hydrolyzed back to GDP, the subunits 
reform to the inactive heterotrimer and associate again with an inactive GPCR (Figure 6). 
Both complexes in the activated G protein can relay messages in the cell by interacting with 
other membrane proteins involved in signal transduction.  Targets for activated G proteins 
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Figure 7. | cAMP stimulates CREB phosphorylation.  
The binding of ligand to GPCRs that are linked to the stimulatory G proteins, which are comprised of α-, β- and 
γ-subunits, leads to the activation of AC, which catalyzes the synthesis of cyclic AMP. Increases in cellular 
cAMP stimulate protein kinase A (PKA) signalling. cAMP binds to the regulatory (R) subunits of PKA, 
thereby promoting their dissociation from the catalytic subunits. The liberated catalytic subunits enter the 
nucleus by passive diffusion and phosphorylate the cAMP-responsive element (CRE)-binding protein (CREB) 
at Ser133. Phosphorylated CREB promotes target gene expression at promoters containing CREs. (Altarejos 
and Montminy 2011) 
 
include various enzymes to produce secondary messengers, as well as specific ion channels 
that allow ions to act as second messengers.  Some G proteins have stimulatory effects and 
others have inhibitory effects (Tuteja 2009).  When 5-HT4 receptor is ligand stimulated, the 
activated GTP bound α subunit diffuses laterally until it interacts with and activates Adenylate 
Cyclase (AC). AC is a membrane bound enzyme that dephosphorylates ATP to cyclic AMP 
(Figure 7). cAMP regulation is directly associated with BDNF levels. There are several 
ligands for 5-HT4R, and one called RS67333 is able to produce AD effects in a short 
timeframe.  
5.2. Gα subunit 
The α subunit has four main families, αs, αi/o αq/11, and α12/13 (Figure 8) (Brandt and Ross 
1985). To date there are 21 different α subtypes of α (Strathmann and Simon 1991; Baltoumas, 
Theodoropoulou et al. 2013). In terms of cAMP signaling, the α subunit can be stimulatory 
(αs) and cause an increase in cellular levels of cAMP (Lania, Mantovani et al. 2012) or can 
also inhibit (αi/o) and decrease cellular levels of cAMP (Roberts and Waelbroeck 2004).  The  
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Figure 8. Diversity of G-protein-coupled receptor signalling 
Various ligands use GPCRs to stimulate membrane, cytoplasmic and nuclear targets. GPCRs interact with 
heterotrimeric G proteins composed of α, β and γ subunits that are GDP bound in the resting state. Agonist 
binding triggers a conformational change in the receptor, which catalyses the dissociation of GDP from the α 
subunit followed by GTP-binding to Gα and the dissociation of Gα from Gβγ subunits 1. The α subunits of G 
proteins are divided into four subfamilies: Gαs, Gαi, Gαq and Gα12, and a single GPCR can couple to either 
one or more families of Gα proteins. Each G protein activates several downstream effectors 2. Typically Gαs 
stimulates adenylyl cyclase and increases levels of cyclic AMP (cAMP), whereas Gαi inhibits adenylyl 
cyclase and lowers cAMP levels, and members of the Gαq family bind to and activate phospholipase C 
(PLC), which cleaves phosphatidylinositol bisphosphate (PIP2) into diacylglycerol and inositol triphosphate 
(IP3). The Gβ subunits and Gγ subunits function as a dimer to activate many signalling molecules, including 
phospholipases, ion channels and lipid kinases. Besides the regulation of these classical second-messenger 
generating systems, Gβγ subunits and Gα subunits such as Gα12 and Gαq can also control the activity of key 
intracellular signal-transducing molecules, including small GTP-binding proteins of the Ras and Rho 
families and members of the mitogen-activated protein kinase (MAPK) family of serine-threonine kinases. 
Ultimately, the integration of the functional activity of the G-protein-regulated signalling networks control 
many cellular functions. (Dorsam and Gutkind 2007) 
 G αq/11 family increases cellular levels of inositol triphosphate (IP3) and diacylglycerol (DAG). 
The G α12/13 are involved in the Rho family GTPases signaling involving the control of cell 
cytoskeleton remodeling and cell migration. Each GPCR complexes with unique Gα subunits 
from one of the four major classes of α subunits, and each class consists of multiple subtypes. 
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For the 5-HT receptors the αs is specific in its interaction with 5-HT4,  5-HT6, and 5-HT7 
receptors.  The αi/o interacts with receptors 5-HT1 and 5-HT5. The 5-HT2 receptor mainly 
interacts with subunit G αq/11 . The G α12/13 has not been observed interacting with any 5-HT 
receptor. The general structure of these α subunit consists of two domains: a GTP binding 
domain and a helical insertion domain subunit. The α subunit is activated by GTP binding and 
dissociates from the G protein complex. When GTP is hydrolyzed back to GDP, the subunits 
reform to the inactive α-β-γ-GDP heterotrimer and associate again with the GPCR. 
5.3. Gβγ subunits 
Gβγ has a wide range of actions having a ‘hot spot’ motif that is key for protein-protein 
reactions.  When Gβγ is in complex with Gα it acts as a negative regulator by increasing Gα’s 
affinity for GDP. When the G protein is in complex with GDP it is in its inactive state 
(Wettschureck and Offermanns 2005). There are five different subtypes of β and twelve 
subtypes of γ discovered so far and they pair for a variety of βx γy (Akgoz, Kalyanaraman et al. 
2004) . It is also noteworthy that certain β subunits will prefer certain γ subunits. Gβγ is 
required for nuclear exchange (Fung 1983; Florio and Sternweis 1989). Gβγ might also be 
necessary for α to engage plasma membrane (Sternweis 1986). As well as placing the α 
subunit into the right orientation and conformation to interact with the receptor, the α subunit 
is in a distinct orientation when unbounded (Lambright, Noel et al. 1994; Mixon, Lee et al. 
1995; Lambright, Sondek et al. 1996). The general structure of the β subunit is 4 stranded β 
sheets forming each of the 7 blades of a propeller. The β propeller interacts with the α helix of 
the N terminal on Gα, inducing a conformational change upon the binding and interacting of 
GTP with the β propeller (Gaudet, Bohm et al. 1996; Sondek, Bohm et al. 1996; Lodowski, 
Pitcher et al. 2003). Gβγ does not cause significant conformation change upon G-protein 
activation with regards to downstream effects (Lucas, Rymar et al. 2007). Gβγ has an 
important role in desensitization and internalization of receptors. In the case of the muscarinic-
3 GPCR, a disruption on the 3
rd
 intracellular loop containing a binding site for Gβγ, did not 
affect downstream signaling, but it did inhibit receptor desensitization. This suggest that Gβγ 
binding to this loop facilitates the recruitment of G protein coupled receptor kinases (GRK) to 
the active form of the receptor (Wu, Bogatkevich et al. 2000). It is not yet known where on the 
receptor or which GRKs interact with the 5-HT4 receptor to be desensitized (Nedi, White et al. 
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2011). But a continual activation will result in increased concentration of intracellular cAMP 
by adenylate cyclase (AC). 
6. The cAMP pathway 
6.1. Secondary cascade 
cAMP is produced when the G protein subunit Gαs  is activated by the receptor and binds to 
and activates the integral membrane protein AC. AC catalyzes the cyclization of ATP, losing 2 
phosphate groups in the process. cAMP production will activate Protein Kinase A (PKA), 
cyclic nucleotide-gated ion channels (Kaupp and Seifert 2002), domain-containing proteins, as 
well as exchange proteins activated by cAMP. PKA is a dimer that is made up of a regulatory 
unit and a catalytic unit. cAMP binds to the regulatory unit of PKA, releasing the catalytic unit 
and allowing it to pass through the nuclear membrane (Figure 7). When in the nucleus, one of 
the PKAs roles is to recruit other transcription factors coactivators to bind the cAMP Response 
Element Binding (CREB) promoter region and activate transcription dependent (Kriisa, 
Sinijärv et al. 2015).  CREB transcription directly affects the levels of expression of 
neurotrophin BDNF, which has a significant role in neurogenesis (Tao, Finkbeiner et al. 
1998).  
6.2.  Downstream targets 
6.2.1. CREB 
CREB is a cellular transcription factor that sequences of DNA in the nucleus, modulating the 
transcription of downstream genes (Montminy and Bilezikjian 1987). CREB regulates genes 
such as c-fos (Sassone-Corsi 1988), BDNF (Nibuya, Nestler et al. 1996), tyrosine hydroxylase 
(McMahon and Sabban 1992), and various neuropeptides (Andrisani and Dixon 1990; 
Hawley, Scheibe et al. 1992; Barthel and Loeffler 1993). Many of the genes it regulates are 
involved in long-term memory formation, long-term potentiation and reward.  
6.2.1.1. CREB and plasticity 
CREB is necessary for neuronal plasticity and long-term potentiation but is not limited to 
neurons and is found in many different organs (Carlezon, Duman et al. 2005). CREB has an 
important role in drug/reward addiction and has been mechanistically linked to behavioural 
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Figure 9. Regulation of cAMP response element-binding protein by drugs of abuse. 
The figure shows a dopamine (DA)-containing neuron from the ventral tegmental area (VTA) that innervates 
a class of GABA-containing projection neurons in the nucleus accumbens (NAc) that express dynorphin 
(DYN). DYN acts as a negative feedback mechanism in this circuit. DYN released from the terminals of 
neurons from the NAc acts on kappa opioid peptide (κ) receptors on nerve terminals and cell bodies of DA-
containing neurons and inhibits their activity. Chronic exposure to either cocaine or opiates and, possibly, 
other drugs of abuse upregulates this negative feedback loop by upregulating the cAMP pathway, which 
activates CREB and induces the formation of DYN.(Nestler 2004)  
 changes in drug addiction (Figure 9) (DiRocco, Scheiner et al. 2009; Nazarian, Sun et al. 
2009; Wang, Ghezzi et al. 2009). Many drugs of abuse lead to changes in expression of 
endogenous BDNF (Barker, Taylor et al. 2014) and c-fos (Wright, Hollis et al. 2015). 
Evidence is growing that low levels of CREB in parts of the brain are associated with 
depression, and increases of CREB have been associated with AD treatment (Gass and Riva 
2007). CREB is modulated by serotonin and noradrenalin binding to GPCRs activating the 
cAMP pathway (Gaven, Pellissier et al. 2013), and dysfunction in these receptors has been 
implicated in MDD (Krishnan and Nestler 2008).  
6.2.1.2. CREB and antidepressant treatment 
CREB is thought to play an important role in AD treatment because of its role in learning-
related synaptic plasticity, neuronal plasticity, long-term memory formation and 
neuroprotective properties (Nair and Vaidya 2006; Tardito, Perez et al. 2006; Gass and Riva 
2007) . The expression and activity of CREB are increased in chronic but not acute treatment 
with AD rodent models and in the human postmortem brain (Nibuya, Nestler et al. 1996; 
Dowlatshahi, MacQueen et al. 1998; Malberg, Eisch et al. 2000; Thome, Sakai et al. 2000). 
Some researchers have reported no change or even a decrease in CREB protein following AD 
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treatment (Blom, Tascedda et al. 2002; Laifenfeld, Karry et al. 2005). This supports the idea 
that ADs affect CREB differently and in different regions of the brain. Targeted treatment 
would enable memory formation in regions of the brain that form happy memories, and reduce 
memory formation in regions of the brain for fear (Frechilla, Otano et al. 1998; Manier, 
Shelton et al. 2002; Laifenfeld, Karry et al. 2005; Berton and Nestler 2006; Yu and Chen 
2011). Expression manipulation studies have associated increased PKA and CREB activity in  
the amygdala with anxiogenic and depressive-like behaviours (Wallace, Stellitano et al. 2004; 
Keil, Briassoulis et al. 2012). In a study by Carlezon et al (2006), CREB appeared to affect 
behaviour differently depending on where it was expressed (Nestler and Carlezon 2006). In 
viral expression of a dominant negative form of CREB, mCREB had a pro-depressant effect 
when localized in the hippocampus, and an AD effect when localized in the amygdala or 
nucleus accumbens (Chen, Shirayama et al. 2001; Pliakas, Carlson et al. 2001; Wallace, 
Stellitano et al. 2004). CREB regulates BDNF which plays a significant role in neurogenesis, 
synaptogenesis and depression. 
6.2.2. BDNF 
6.2.2.1. BDNF-mediated Neural regulation 
BDNF regulates neuronal structure and function (Schinder and Poo 2000; Tyler, Alonso et al. 
2002). It is critical for synaptic plasticity and memory processing (Alonso, Vianna et al. 2002; 
Tyler, Alonso et al. 2002; Yamada and Nabeshima 2003; Bekinschtein, Cammarota et al. 
2007). BDNF induces and is sufficient for long-term potentiation in the hippocampus (Kang, 
Welcher et al. 1997; Patterson, Pittenger et al. 2001; Pang, Teng et al. 2004; Pastalkova, 
Serrano et al. 2006). Physical and social stresses lead to decreased levels of BDNF in the 
hippocampus and prefrontal cortex (Duman and Monteggia 2006; Krishnan and Nestler 2008; 
Castrén and Rantamäki 2010). AD Treatment increases the expression of BDNF in the 
hippocampus and prefrontal cortex. This upregulation is only observed in chronic and not 
acute administration of different ADs (Duman and Monteggia 2006; Sen, Duman et al. 2008; 
Bocchio-Chiavetto, Bagnardi et al. 2010). Depression results in neuronal atrophy and 
decreased neurogenesis (Taylor, McQuoid et al. 2014). Treating with ADs blocks and can 
reverse this neurotrophic deficit, reversing the atrophy and cell loss (Duman, Heninger et al. 
1997; Duman and Monteggia 2006). Certain regions of the brain vary in respect to BDNF 
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levels.  An increase in BDNF in the hippocampus has AD effects, while in the nucleus 
accumbens or amygdala BDNF effects may be pro-depressive (Duman and Monteggia 2006; 
Krishnan and Nestler 2008).  
6.2.2.2. BDNF and depression 
Though BDNF depletion may not be sufficient to cause depressive behavior, an absence of it 
in specific regions of the brain may increase susceptibility to becoming depressed under 
stressful conditions. A study by Ibarguen-Vargas et al (2009) made use of a mouse model that 
had heterozygous deletions of BDNF and expressing approximately half the normal levels of 
BDNF. Under baseline conditions these mice were non symptomatic, but upon exposure to 
stress, they more readily exhibited depressive symptoms (Duman, Russell et al. 2007; 
Ibarguen-Vargas, Surget et al. 2009). Different types of acute and chronic physical and social 
stress also decrease neurogenesis while chronic AD treatment increases neurogenesis. As 
described in figure 2, the expression of BDNF has a positive feedback loop both for positive 
effects and negative effects. Exercise and social interactions both short term and long term 
lead to an increase in BDNF (Szuhany, Bugatti et al. 2015). Expression of BDNF has been 
linked to increased happiness (Castren 2014),  neuronal activity, neurogenesis (Jeong, Kim et 
al. 2014) and synaptic plasticity. These in turn are linked to increased social interaction 
(Hsiao, Hung et al. 2014). On the other hand, a lack of physical exercise, or increases in stress 
may lead to a decrease in neuronal activity.  A decrease in neuronal activity may lead to 
atrophy and apoptosis, decreasing BDNF expression, potential increasing stress levels (Ieraci, 
Mallei et al. 2015) and continuing the cycle.  
An effective AD would increase the expression of pCREB and BDNF in specific regions of 
the brain related to reward and motivation. This effect would be rapid, sustainable and would 
not overstimulate the receptors enough to cause desensitization. 
7. Regulation and desensitization 
7.1. GRK 
GRKs are a family of protein kinases that regulate GPCRs .There are seven mammalian GRKs 
grouped into three subfamilies: GRK1 comprising of GRK1 (rhodopsin kinase) and GRK7 
34 
 
 
Figure 10. G-protein-coupled receptor (GPCR) desensitization, internalization and down-
regulation.  
Upon activation of the GPCR, GPCR kinase (GRK) phosphorylates the receptor, generally on C-terminal 
Ser/Thr residues. Once phosphorylated, β-arrestin can bind to the GPCR, desensitizing the receptor and 
causing the receptor to internalize via clathrin-coated pits. Once internalized, GPCRs may be recycled back 
to the cell surface following dephosphorylation in acidified endosomal compartments. Alternatively, GPCRs 
can be trafficked to lysosomes and degraded (down-regulation), a process that is facilitated by GPCR-
associated sorting protein (GASP)(Smith, Sim‐Selley et al. 2010). 
 
(cone kinase), GRK2 comprising of GRK2 and 3, and GRK4 comprising of GRK4,5 and 6 
(Premont, Macrae et al. 1999).  The first 20 amino acids of GRKs are highly conserved and 
are critical for GPCR and phospholipid-stimulated autophosphorylation. They have a 
multidomain structure comprised of three functional domains, a central catalytic domain,  an  
amino-terminal regulator of G protein signalling homology,  and a carboxyl-terminal 
membrane targeting domain (Pronin and Benovic 1997; Lodowski, Pitcher et al. 2003; 
Tesmer, Kawano et al. 2005). GRKs will phosphorylate serine and/or threonine residues on 
the third intracellular loop and carboxyl-terminal tail domains of agonist activated receptors. 
Phosphorylation is a necessary step for the termination of an active signal from GPCR, but it 
on its own is insufficient to mediate the desensitization of many GPCRs (figure 10). The 
phosphorylation converts it into a target of high affinity binding of arrestin proteins and 
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phosphorylated GPCRs facilitates the uncoupling of the receptor from the heterotrimeric G 
proteins.       
7.2. Arrestins 
There are four different subtypes of arrestin proteins in mammals, named Arrestin 1, βarrestin, 
βarrestin2, and Arrestin4. They primarily participate in agonist mediated desensitization of 
GPCR, causing specific dampening of cellular response to stimuli such as hormones, sensory 
signals and in our case neurotransmitters.  GRK mediated phosphorylation promotes the 
binding of βarrestins 1 and 2 which function as endocytic adaptor proteins that facilitate the 
targeting of receptors for clathrin mediated endocytosis (Figure 11) (Ferguson, Zhang et al. 
1996; Goodman Jr, Krupnick et al. 1996). βarrestin and βarrestin2 were named for their ability 
to sterically hinder the G protein coupling of agonist-activated GPCR, resulting in receptor 
desensitization. They also function to activate signaling cascades independent of G protein 
activation. Serving as multiprotein scaffolds, they bring elements of specific signaling 
pathways into close proximity of the GPCR and of the cell membrane, where many of the 
secondary messengers of G proteins are generated.  βarrestins bring components of the 
clathrin-coated pit machinery, thus stabilizing the association with clathrin-coated pits 
(Laporte, Oakley et al. 2000). The pits invaginate and are released into the cytosol as free 
clathrin coated vesicles. This step requires the activity of dynamin to pinch off the clathrin-
coated vesicle from the plasma membrane (Laporte, Oakley et al. 2000). Following vesicle 
scission, all components must be disassembled so that the clathrin-coated vesicle can fuse with 
an early endosome. This early endosome controls the activity and the destinations of proteins 
in the compartment. These endosomes are a key point for sorting receptors which can be 
directed to late endosome or lysosomes for degradation or  recycling back to the cell surface 
(Mellman 1996).  
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Figure 11. β-Arrestin-dependent internalization of GPCRs. 
 After agonist (A) binding to G-protein-coupled receptors (GPCRs), GPCR kinases (GRK) phosphorylate 
residues in the third intracellular loop and carboxyl tail of GPCRs, leading to the recruitment of beta-arrestins 
(betaARR). The beta-arrestins recruit clathrin and the AP-2 complex, which target GPCRs for clathrin-
mediated endocytosis (Pierce and Lefkowitz 2001). 
 
 
8. Hypothesis of work 
Ligands that activate receptor 5HT4 induce conformational changes that differ in the 
recruitment of G protein αs and αo. This functional selectivity may account for RS67333’s 
antidepressant implications. 
9. Goal of project 
Different agonists that activate the same GPCR are in some cases capable of producing 
different response profiles through activation of different types of G proteins (Urban, Clarke et 
al. 2007). Functional selectivity is thought to be due to the stabilization of different 
conformations of GPCR by agonists leading to activation of different sets of responses (Perez 
and Karnik 2005; Urban, Clarke et al. 2007). To this end different agonists could also lead to 
different mechanisms of desensitization, as each agonist-induced GPCR conformation could 
possess different affinities for regulatory proteins such as GRKs and arrestins.  RS67333 is a 
5-HT4 agonist that has lasting AD effects in a short time (Mnie-Filali, Amraei et al. 2010; 
Vilaró and Piñeyro 2010). Our objective is to profile five 5-HT4 agonists: Zacopride, 
Prucalopride,  ML10302, RS67333 and Serotonin. We will be profiling them with respect to 
the cAMP pathway, measuring conformational changes in Gαs and Gαo,  with the BRET 
technique, measuring desensitization with ELISA, and measuring changes in pCREB in the 
nucleus accumbens and striatum when treated with RS67333. 
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Materials and Methods 
1. pCREB Measurements in striatum and nucleus accumbens in OBX versus sham rats 
1.1. Olfactory bulb ablation 
Rats were anesthetized with a mixture of isoflurane (3– 3.5%) and oxygen (Breuer, Groenink 
et al. 2007) and mounted onto a stereotaxic apparatus. An incision was made on the scalp and 
a rectangular hole was drilled on the portion of the skull overlying the olfactory bulbs. The 
caudal end of the bulbs was then severed from the rostral pole of prefrontal cortex with a 
microknife; physical transection of the junction between these two structures precluded 
distortion to the prefrontal cortex during removal of the olfactory bulbs by suction (van der 
Stelt, Breuer et al. 2005). The resultant cavity was then filled with sterile hemostatic sponge 
and the wound was closed with sterile suture (van der Stelt, Breuer et al. 2005; Breuer, 
Groenink et al. 2007). Sham-operated (SHAM) rats were treated similarly, with the exception 
that their brain remained intact. Following surgery, all rats were housed singly and allowed a 
minimum of 10 days to recover prior to the start of behavioral testing. Each brain was 
inspected at the time of sacrifice; bulbectomies were considered successful only if less than 
30% of the bulbs remained intact (van Riezen, Schnieden et al. 1977; Chambliss, Van 
Hoomissen et al. 2004). 
1.2. Preparation of brain samples 
Following the removal of residual bulb in the rats, striata and nucleus accumbens were 
dissected on ice. Dissection and determination of CREB activity was performed using the 
methods described by Lucas et al. (Lucas, Rymar et al. 2007). Isolated striata, including the 
ventral striatum (1-2 mg wet tissue/100 μl) were homogenized in buffer containing 5 mM 
Tris-HCl, pH 7.4, 2 mM EDTA, and protease inhibitors (5  g/ml leupeptin, 5  g/ml soybean 
trypsin inhibitor, and 10  g/ml benzamidine (Lucas, Rymar et al. 2007). After homogenization, 
Triton X-100 was added at a final concentration of 1% (v/v) and the mixture was agitated (4° 
C, 1.5 h) followed by centrifugation  (4°C, 15,000xg, 25 min).  The resulting pellet was 
suspended in sample buffer at a final concentration of 10 μg protein/μl.  
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1.3. Membrane Preparation 
Membranes were prepared as described previously (Rousseau, Nantel et al. 1996). Briefly, 
washed tissues were then lysed on ice with a Branson sonifier 250 VWR scientific (ten 1-
second bursts at maximum speed). Lysates were then heat shocked for 5 min at 95 °C, cooled 
on ice, followed by centrifugation at 500g for 5 min at 4°C, and the resulting supernatant was 
centrifuged at 45,000g for 20 min at 4°C. The resulting pellet was resuspended in binding 
buffer (75 mM Tris-HCl, pH 7.4, 12.5 mM MgCl2, 2 mM EDTA, and protease inhibitors as 
indicated above) and immediately used in binding assays or for gel electrophoresis. Protein 
concentration was determined using the Bio-Rad DC Protein Assay Kit (Richmond, CA) and 
300 μg of protein was used. For SDS-polyacrylamide gel electrophoresis, membrane protein 
samples were denatured in sample buffer (62.5 mM Tris-HCl, 5% SDS, 50 mM dithiothreitol 
(DTT), 10% glycerol, 0.05% bromophenol blue) and separated on a 10% Sodium Dodecyl 
Sulfate-polyacrylamide gel (SDS-PAGE) using a GE healthcare Rainbow
TM
 Molecular weight 
marker as the ladder . 
1.4. Preparation of SDS-PAGE  
There are two types of gel: running gel and stacking gel. The running gel is made 3.97 ml of 
H2O,  3.33 ml of  Acryl-bisacryl,  2.5 ml of Tris 1.5M pH 8.8, 100  μL  of 10% Sodium 
dodecyl sulfate (SDS), 100  μL  of ammonium persulfate and lastly 5  μL of 
Tetramethylethylenediamine (TEMED). The stacking gel has a slightly different blend, still 
using all the same ingredients except with a change to Tris 0.5 M pH 6.8. Stacking gel uses 
2.38 ml H2O, 500 μl of acryl-bisacryl, 500 μl of Tris 0.5M pH6.8, 38 μl of  10% SDS, 38 μl of 
10% APS, and 4 μl of TEMED.  
1.5. Western blot analysis 
The samples were sonicated and immediately boiled for 5 min before being inserted into gels 
(SDS-PAGE). A running buffer of 30 mM Tris base, 50 mM glycine, and 3 mM SDS was 
used. The gels were run at 170V for 2 hours. The proteins resolved in SDS-PAGE were 
transferred from gels onto nitrocellulose in a transfer buffer solution of 0.025M Tris base, 0.19 
M glycine, 10% methanol, via a current (50 mA, overnight, Bio-Rad).  The phosphorylated 
39 
 
form of CREB (pCREB) was detected by probing membranes with an mouse anti-pCREB 
monoclonal antibody (1: 100; sigma) followed by secondary antimouse (1:5000; Sigma). Total 
CREB content was determined after stripping by using a 1:5000 dilution of anti-CREB 
polyclonal antibody (Cell Signaling Technology) followed secondary anti-rabbit  horseradish 
peroxidase (HRP)-conjugated IgG  antibodies (1:10000; Amersham). Protein content was 
revealed by chemiluminescence detection reagents (Amersham ECL select).The density of 
each band was quantified using the ImageJ software (National Institutes of Health, USA). The 
results were expressed as the pCREB/total-CREB ratio. The activation of CREB in striatum 
and Nucleus Accumbens tissue was assessed by measuring phospho-CREB (pCREB) 
immunoreactivity. CREB phosphorylation was normalized according to the amount of protein 
present in each sampled by expressing the data as a ratio of pCREB over total CREB 
immunocreactivity. 
2. BRET Comparisons between RS67333, 5-HT and other ligands 
2.1. Cell Culture  
2.1.1. Cell line 5-HT4b  
Stable cell lines were produced using lipofectamine (Invitrogen) to transfect 4 μg of  
DNA/100 mm petridish followed by selection with Geneticin (500 μg/ml). Cells containing 
the 5-HT4B receptor would have resistance to the antibiotic G418.  The 5-HT4B stable cells   
were used for internalization experiments and kept stable with typical DMEM media with 
10% FBS, penicillin, streptomycin and G418.  
2.1.2. Transfection of HEK 293 immortal cell line 
HEK293 cells were cultured in DMEM (Dulbecco's Modified Eagle Medium) supplemented 
with 10% FBS, and penicillin 1000 Units/ml and 1mg/ml Streptomycin (Wisent. Inc.) at 37°C, 
in 5% CO2 and 100% humidity. Aliquots of 3.5 x 10
6
 cells were seeded into 10-cm dishes to 
optimize transfections conditions. Aliquots of 3.5 x 10
6
 cells were incubated overnight. 
Transient transfection were performed the following day with polyethylenimine (PEI)  in 
DMEM media (Pei: Polysciences) at a DNA/PEI ration of 1:2. The DNA to study the 
conformational changes in αs and γ2 were 0.4 μg of αs67RlucII, 4 μg of γ2GFP
10, 4 μg of β1 
and 8 μg of HA-5-HT4B. The DNA to study the conformational changes in αo and γ2 were 0.35 
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μg of αo90RlucII, 3 μg of  γ2GFP
10, 3 μg of β1 and 10 μg of HA-5-HT4B.. They were incubated 
for 3 hours and the transfection was stopped by removing media and replacing with the same 
growth media used previously. They were then incubated for 2 nights and were then ready for 
experiments using Bioluminescence resonance energy transfer (BRET).  
2.2. BRET  
2.2.1. DNA constructs  
The plasmids encoding the Green Fluorescent Protein (GFP
10
) fused at the N terminus of the 
human Gγ2 were obtained by subcloning the human Gγ2 coding sequences into GFP vectors 
(Gales, Van Durm et al. 2006).  Recombinant plasmids encoding for αsRlucII were prepared as 
previously described (Audet, Gales et al. 2008), to insert the coding sequence of humanized 
Renilla luciferase (Rluc; PerkinElmer Life Science) into the coding sequence of human Gαs   at  
Ser
67
.  They were donated to us as a gift from the Michel Bouvier’s laboratory. The vector 
encoding human influenza hemagglutinin (HA) fused in frame at the N terminus of human 5-
HT4B have been previously described (Breit, Gagnidze et al. 2006).  
2.2.2. BRET Analysis 
Gα and Gγ2 were tagged with Rluciferase II  at the 67
th
 amino acid and with GFP10 at the N 
terminus. Forty eight hours after transfection, cells were washed twice and mechanically 
detached with phosphate buffered saline (PBS) and centrifuged 5 min at 300g, followed by 
resuspension in PBS. Treatments and BRET protocols were based on a previously established 
protocol that was optimized for assessing in vivo ligand effects on receptor interaction with 
heterotrimeric G proteins (Gales, Van Durm et al. 2006; Rebois, Robitaille et al. 2006). Cells 
were briefly kept on ice until immediately prior to reading. They were then distributed into a 
96-well microplate (white optiplate; PerkinElmer Life Sciences) at a concentration of 1.5 μg 
protein/well, which allowed us to achieve luminescence levels suitable for BRET readings 
using different constructs. The Rluc coelenterazine substrate DeepBlueC (PerkinElmer Life 
Sciences) was added for a final concentration of 5 μM. Readings were taken 10 min after 
coelanterazine addition, using the Mithras LB 940 multimode microplate reader that allows 
the sequential integration of the signals detected in the 400 nm and 515 nm windows using 
filters with the appropriate band pass (chroma). The BRET2 signal was determined by 
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calculating the ratio of the light emitted by GFP10 (515nm) over the light emitted by the 
RlucII (400nm) at the detection wavelength of the filters. BRET2 values were corrected by 
subtracting the BRET background signal measured from the Rluc-tagged construct alone, from 
the BRET signal detected in cells co-expressing both Rluc and GFP (net BRET).  
2.2.3. BRET theory 
BRET makes use of the naturally occurring phenomenon  luciferase to excite the fluorescently 
bound proteins and measure the non-radiative transfer of energy between a luminescent donor 
and a fluorescent acceptor (Angers, Salahpour et al. 2000). In BRET2 assays, Rluc catalyses 
the oxidation of cell permeable coelenterazine (Deepblue C) resulting in luminescent 
emissions within the excitation wavelength of GFP (Bertrand, Parent et al. 2002). Because the 
efficacy of the energy transfer varies inversely with the sixth power of distance, fluorescence 
emission by GFP will only take place if donor excitation occurs in close proximity of the 
acceptor (100 Angstroms). This property may be exploited to monitor interactions between 
different types of cellular proteins (Milligan and Bouvier 2005; Marullo and Bouvier 2007) 
provided that the proteins of interest are tagged with donor/acceptor pairs. Changes in the 
BRET ratio implies movement of the donor and acceptor protein in relation to each other, and 
can only be observed if proteins are within 20Å of each other (Altenbach, Oh et al. 2001). 
3. Ligand Induced internalization studies 
3.1. ELISA assays of cell internalization 
For quantification of receptor internalization, enzyme linked immunosorbent assays (ELISA) 
were performed. Cells stably expressing the 5-HT4B  receptor were plated out at 200,000 cells 
per well of a 24 well tissue culture dish previously coated with 0.1 mg/ml poly-l-lysine and 
incubated in DMEM 10%FBS with G418. After 24 hours the cells were serum-deprived and 
incubated at 37°C overnight.    The cells were then incubated for 90 min at 37°C under the 
conditions of agonist stimulation (serotonin, RS67333, Zacopride, Prucalopride and 
ML10302) at various concentrations.  Stimulation was stopped by removing the media and 
fixing the cells with 3% paraformyladehyde/PBS for 15 min on ice. The cells were then 
washed two times with PBS-CM (1 mM MgCl2, 1 mM M CaCl2) on ice. Non-specific binding 
was blocked with PBS-CM/BSA (1%) for 30 min at room temperature. The primary antibody 
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(monoclonal mouse anti-HA) was added at a dilution of 1/3000 in PBS/BSA for 1 hour at 
room temperature/ two washes of PBS followed.  Incubation with HRP linked anti-Mouse IgG 
diluted to 1/5000 for 30 min. The cells were then washed twice with PBS-CM and 200μl of 
HRP o-phenylelediamine dihydroschloride (sigma FASTTM OPD) colorimetric alkaline 
phosphatase substrate was added. When the adequate color change was reached, coloration 
was stopped by adding 50μl HCl 3N and 200μl samples were taken for colorimetric readings. 
The optical density was measured at 492 nm in a 96-well microplate (Victor3 Plate reader; 
Perkin Elmer) The optical density (OD) corresponds to the signal generated by receptors 
bound on the cell surface. The quantity of receptors internalized immediately after the 
exposition to the drugs was calculated by using the OD in the presence  and  absence of drugs. 
The results express the percentage of receptor present at the surface in a ratio 
:
ODbasal−ODstimulated
ODbasal
∗ 100% , where ODbasal and ODstimulated were the optical densities of the 
receptors in absence or in presence of respective agonist at different concentrations.  The value 
obtained correspond to the results of internalization in percentage of the receptors on the 
surface with treatment. The results of different treatments are compared to the normalization 
of internalization induced by 5-HT. 
3.2. 5-HT4  receptor ligands 
We used 5-HT, a ubiquitous endogenous neurotransmitter ligand important in learning, mood, 
and sleep (Portas, Bjorvatn et al. 2000; Harvey 2003; Ruhé, Mason et al. 2007). Zacopride is 
an exogenous ligand that is an antagonist of the 5HT3 receptor (Smith, Sancilio et al. 1988) 
and an agonist for the 5-HT4 receptor (Lefebvre, Contesse et al. 1993). Prucalopride, an 
exogenous ligand, is an agonist for the  5-HT4 receptor (Briejer, Bosmans et al. 2001). 
ML10302, an exogenous ligand, may be a partial agonist for the 5-HT4 receptor. Finally,  
RS67333 is an exogenous ligand that acts on the 5-HT4 receptor as an agonist (Lamirault and 
Simon 2001). 
4. Statistical analysis 
All statistical analyses were performed using Graphpad 6 (Prism) software package. 
Means of two experimental conditions run in parallel were analyzed by means of paired, 
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two-tailed Student’s t tests. Multiple comparisons were done by means of ANOVA-two 
way analysis. After establishing significance for different factors and interactions, posthoc 
tests were carried out to further establish the source of differences. When all conditions 
were compared among each other the test used was Tukey’s; when selected conditions 
were compared the test used was Sidak’s. The effects of drug concentrations were 
established using Dunnet’s test to compare responses obtained in the presence of ligand to 
responses obtained in its absence.    
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Results 
1. Olfatory Bulbectomy and pCREB in striatum and nucleus accumbens 
Our aim in this part of the project was to determine whether normalization of Olfactory 
Bulbectomy (OBX)-induced anhedonia by RS67333 administration is accompanied by 
modulation of pCREB in reward relevant sites. It has previously been shown that OBX- 
induced anhedonia is associated with dysregulation in brain levels of the phosphorylated form 
of CREB (pCREB) (Romeas, Morissette et al. 2009).  Indeed, this transcription factor is 
expressed in reward sites of the brain, in healthy individuals, and is necessary for neuronal 
plasticity, and where it modulates hedonic responses (Carlezon, Duman et al. 2005; Nestler 
and Carlezon 2006) .   
1.1. Sucrose intake and changes in pCREB 
Changes in CREB in the striatum and the accumbens have been correlated with sucrose intake 
and decreased reward by morphine and cocaine (Carlezon, Thome et al. 1998; Pliakas, Carlson 
et al. 2001; Barrot, Olivier et al. 2002). We used western blot analysis to determine the effects 
of RS67333 on the pCREB/TCREB ratio inside the striatum and nucleus accumbens, a brain 
structure directly involved in reward processing.  The effects of RS67333 were assessed in 
two different groups of rats: i) rats that were subject to OBX and ii) rats that were subject to a 
sham operation. Results from these experiments are shown in Figure 12 and 13. 
1.2. Rats treated with RS67333 had increase in pCREB 
 In keeping with previous reports (Lucas, Rymar et al. 2007), pCREB appeared as an 
immunoreactive band at 46 kDa.  A band corresponding to the total amount of CREB was 
present in the sample and was observed at a similar molecular weight. Quantification of 
corresponding pCREB/tCREB ratios for different treatments are shown in Figure12A and 
indicate that exposure to RS67333 enhanced the proportion of CREB in its phosphorylated 
state within the striatum of OBX treated rats. The ratios in the striatum were 0.91 ± 0.04 for 
SHAM animals treated with vehicle and 0.97 ± 0.08 for SHAMs treated with RS67333. For 
animals that had undergone ablation of OBX and were treated with vehicle the pCREB/tCREB  
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Figure 12. Effect of selective 5-HT4 receptor ligand RS67333 on the activation of CREB 
in rat striatum, assessed by measuring phospho-CREB (pCREB) immunoreactivity.  
pCREB levels were assessed by western blot analysis carried out in striatal samples of the indicated groups of 
animals:  Sham operated +Vehicle treatment (SV), Sham operated +RS67333 treatment (SR), OBX operated 
+Vehicle treatment (OV) and OBX operated +RS67333 treatment (OR). The sacrifice of rats occurred on the last 
day of a 7 day treatment regimen. (A) Representative samples of pCREB and totalCREB immunoreactivity from 
each group. Samples were obtained from the same blot and spliced in order to remove molecular weight markers. 
Bands appeared at ~ 46 kDa. (B) Here, we estimated activity from the ratio between the phosphorylated form and 
total CREB protein present in each sample (pCREB/totalCREB). Ratios were used in order to normalize 
phosphorylation to the amount of protein present in each sample. Bars representing mean ± s.e.m of 
pCREB/CREB ratios. Ratios were compared by 2 way anova which showed an effect of treatment (p=0.0190) no 
effect of lesion (p=0.0842), and no interaction (p=0.0880). The effect of treatment accounted for 16.5% of the 
total variance.  A post hoc Sidak test allowed comparison of control versus treatment in the sham and lesion 
groups showing an effect of RS67333 in the latter group (p<0.05).  
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B 
pCREB 
totalCREB 
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 Figure 13. Effect of selective 5-HT4 receptor ligand RS67333 on the activation of CREB 
in rat nucleus accumbens, assessed by measuring phosphoCREB (pCREB) 
immunoreactivity. 
pCREB levels assessed by western blot analysis carried out in nucleus accumbens samples of the indicated 
groups of animals. (A) Representative samples of pCREB and totalCREB immunoreactivity from each group. 
Samples were obtained from the same blot and spliced in order to remove molecular weight markers. Bands 
appeared at ~ 46 kDa. (B) ) Here, we estimated activity from the ratio between the phosphorylated form and total 
CREB protein present in each sample (pCREB/totalCREB). Ratios were used in order to normalize 
phosphorylation to the amount of protein present in each sample. Bars representing mean ± s.e.m of 
pCREB/CREB ratios. Ratios were compared by 2 way anova which showed an interaction effect (p<0.0001) no 
effect of lesion (p=0.9192), and no effect of drug (p=0.9856). The interaction effect accounted for 45.9% of the 
total variance.  A post hoc Sidak test allowed comparison of control versus treatment in the sham and lesion 
groups showing an effect of RS67333 in the both groups (p<0.01).  
pCREB 
totalCREB 
A 
B 
Sham+Vehicle =9 
Sham+RS67333 = 9  
OBX+Vehicle = 8 
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ratio was 0.90 ± 0.04 and for OBX rats that had received RS67333 the ratio was 1.27 ± 0.13. 
A post hoc sidak test values indicated that treatment with RS67333 significantly increased this 
ratio in OBX (p <0.005) but not control animals (Figure 12B). The ratios in the accumbens 
were 0.95 ±0.04 for SHAM animals treated with vehicle and 0.57 ± 0.06 for SHAM animals 
treated with RS67333. These values indicated that RS67333 significantly decreased this ratio 
in SHAM (p<0.005). For OBX animals that were treated with vehicle the pCREB/TCREB 
ratio was 0.56 ± 0.09 and for OBX rats that had received RS67333 the ratio was 0.94 ± 0.15. 
These values indicated that RS67333 significantly increased this ratio in OBX (p <0.0001) but 
not control animals (Figure 13B). 
1.3. Rationale for Bioluminescence resonance energy transfer experiments (BRET) 
RS67333 seems to produce a biphasic effect in some cases; meaning it has the ability to 
increase or decrease phosphorylation of CREB. Therefore, it stands to reason that it has the 
ability to increase or reduce signaling though the cAMP pathway. In order to address this 
question, we looked at the first step in the activation of the cAMP pathway which is the 
activation of the Gαs and Gαo protein. We chose to look at the activation of Gαs and Gαo. We 
chose Gαo because this is the G protein most abundant in the Central Nervous System (CNS) 
that inhibits AC (Strittmatter, Valenzuela et al. 1990).  To measure these interactions we used 
Bioluminescence Resonance Energy Transfer (BRET) to compare different ligands.  
2. Comparison of 5-HT4  receptor ligands in their ability to activate cAMP 
2.1. Bioluminescence resonance energy transfer (BRET)  
Bioluminescence resonance energy transfer (BRET) enables us to measure changes in protein 
to protein interactions, and we used this technology to characterize initial steps in the cAMP 
pathway.  5-HT4 receptors interact with and activate Gαs and Gαo. When Gαs is activated, it 
binds to and activates adenylyl cyclase which converts adenine triphosphate (ATP) into cAMP 
(Kammer 1988). When Gαo is activated, it mainly inhibits AC activity.  Here we used a BRET 
biosensor in which the donor luciferase is placed at position 67 on αs (αs67RlucII) or at 
position 90 for αo (αo90RlucII), and the acceptor GFP
10
 is placed at the N-terminus of Gγ2 
(γ2GFP
10).  Since Gαs and Gαo act in opposition, we wanted to measure the conformational 
changes of the Gαβγ in response to the signal activated receptor 5-HT4. In basal conditions, 
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Gαs or Gαo and Gβγ form a complex in which the donor and the acceptor are located close 
enough to one another generating a basal BRET signal. During activation, Gαs will have a 
conformational change relative to Gβγ and increase the BRET signal. In the case of Gαo the 
conformational change relative to Gβγ will result in a decreased BRET signal.  The Gα 
subunits are between 350 and 400 amino acids (Strathmann and Simon 1990). The difference 
in position of the placement of RlucII between Gαs and Gαo is only 23 amino acids. But in a 
quaternary structure the residues positions, and thus the position of RLucII are in different 
environments and distance relative to the γ2GFP
10
 complex. The ligand-activated signal 
induces a conformational change in this quaternary resulting in changes to the BRET signal.   
We took advantage of these properties to determine the ability of 5-HT4 receptor agonists to 
activate αs and αo. 
2.1.1. 5-HT4 receptor  ligands dose response 
5-HT4 receptor agonists were tested at concentrations from 1 nM to 10 μM for a 2 minute 
exposure, sufficient for evaluation of conformational rearrangements within the Gαβγ  
complex (Audet, Gales et al. 2008). We compared the BRET signal of the endogenous ligand, 
5-HT, to the exogenous ligands:  RS67333, Zacopride, Prucalopride and ML10302 that are 
known agonists for the 5-HT4 receptor. Dose response curves for these different ligands are 
shown in Figure 14 and 15;  they indicate that these drugs differ in their ability to activate the 
Gαs, Gαo protein. These values were obtained by attributing 100%  for  Gαs and -100% for Gαo 
to the greatest concentration (10
-4
 M) measured of the endogenous ligand, 5-HT.  The -100% 
for Gαo was attributed because the ligand induced conformational change resulted in a 
decreased BRET signal from basal conditions. 
2.2. Gαs 
2.2.1. EMax and EC50   
5-HT behaved as a full agonist for Gαs producing the greatest Emax. Standardizing 5-HT’s 
maximal effect to 100% we determined the Emax values of the other agonists. To standardize 
each experiment, given that 5-HT is the endogenous ligand, the delta net BRET value at it’s 
highest concentration (10
-4  
[M]) was given the value of 5-HT. Results were analyzed by 
nonlinear regression three parameter analysis agonist vs. response. The Emax of 5-HT was 93.2  
49 
 
 
 
Figure 14. Dose response of 5-HT4  receptor ligands as measured by a BRET-based 
conformational biosensor monitoring αs/γ2 interaction. 
HEK293 cells are transfected with 0.4 μg of αs67RlucII, 4 μg of γ2GFP
10,4 μg of β1 and 8 μg of HA-5-HT4B and 
exposed to agonist for 2 minutes before taking BRET measurements. (A) The Net BRET signal change of the 
interaction with 5-HT. The complex thus formed increased BRET signal under basal conditions. Results were 
compared by means of paired, two tailed Student’s t test with a significant difference of p=0.0003.(B) Results 
represent change with respect to Basal BRET (0.113 ±0.002) and correspond to the mean ± SEM of 7 
independent experiments. Curves were compared by means of 2 way ANOVA which indicated an effect of drug 
of 35.0 % (p<0.0001), a concentration effect of 33.7% (p<0.0001) and an interaction of 16.1% (p<0.0001).  
Posthoc analysis by using Sidak comparison test indicated that RS67333, Zacopride, prucalopride and ML10302 
were all different from the endogenous ligand 5-HT (p<0.0001);  Prucalopride was different from RS67333 
(p<0.05) and ML10302 (p<0.0001) and Zacopride was different from ML10302 (p<0.0001). The effect of 
concentration was analyzed using Dunnett’s test to compare the response in the absence of ligand to responses 
obtained at difference concentrations. Statistical significance is shown on graph. 
  
A 
B 
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Table I. Emax  and EC50 values obtained from dose response curves generated of 5-HT4 
receptor ligands as measured by a BRET through αsRlucII/γ2GFP
10
 interaction (figure 
14B) 
 
EC50(nM) ± s. e. m. Emax± s. e. m. 
5-HT 34.6 ± 2.5  0.0411 ± 0.003 
Zacopride 272 ± 3.8
 
0.0248 ± 0.003 
 
Prucalopride 93.3 ± 3.6  
 
0.0235 ± 0.002 
 
RS67333 23.6 ± 4.2 
 
0.0203± 0.006
 
ML10302 n/a n/a 
  
A 1-way anova determined overall significant variation across EC50 for the different ligands with a p<0.0001. 
Post hoc Sidak multiple comparison test allowed us to establish the following rank order: the EC50 value for 
Zacopride was significantly higher than for Prucalopride (p<0.0001), that of prucalopride was significantly 
higher than that of RS67333(p<0.0001) but not different from that of 5-HT, which in turn did not differ from that 
of RS67333. A 1-way anova determined overall significant variation across Emax for the different ligands with a 
p<0.0001. Post hoc Sidak multiple comparison test allowed us to establish the following rank order: the Emax 
value for 5-HT was significantly higher than for RS67333 (p<0.01) and Zacopride (p<0.05), that of zacopride did 
not significantly differ from prucalopride and RS67333.  
 ± 2.5, Zacopride 48.4% ± 3.2, Prucalopride 47.3% ± 3.6, RS67333 15.6% ± 3.2, and 
ML10302 which was negligible. Gαs activation is critical for the activation of AC, the  
membrane bound protein that hydrolyzes ATP to produce cAMP.  Gαs conformation is 
maximally effected by 5-HT.   The EC50 values for 5-HT, RS67333,  Prucalopride, Zacopride 
and ML10302 are as follows: 34.6 nM ± 2.5 , 23.6 ± 4.2  nM, 93.3 ± 3.6  nM, 272 ± 4 nM, and 
not significant for ML10302 respectively.  RS67333 requires less drug to reach it’s EC50. 
Having said that, RS67333 had an EMax of 16% of what the endogenous ligand, 5-HT, obtains. 
Prucalopride and Zacopride require 3x and 9x of their respective drug compared to 5-HT to 
reach their EC50 and their Emax are 47% and 48% respectively. ML10302 did not significantly 
change from basal conditions. Using Sidaks multiple comparison test for the Emax values we 
established the following rank order of efficacies in the activation of αs: 5-HT>Zacopride = 
Prucalopride> RS67333>ML10302 (p < 0.0001). In terms of potency in the activation of αs, 
using Sidak’s multiple comparison test with the EC50 results, we establish a rank order of 5-
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HT = RS67333 > Prucalopride > Zacopride > ML10302 (p < 0.0001).Taken together this data 
indicates that RS67333,Zacopride, and Prucalopride behave as  partial agonists in the 
activation of Gαs. 5-HT as the endogenous ligand behaves a full agonist, and has a similar 
potency to RS67333. ML10302 has negligible efficacy as an agonist for Gαs.  
2.3. Gαo 
2.3.1. EMax and EC50 
5-HT behaved also as a full agonist for Gαo producing the greatest Emax. Standardizing the 
maximal effect to -100% we determined the Emax values of the other agonists. The Emax of 5-
HT was -102.3% ±  6.2,  Prucalopride -57.7% ±6.2,  ML10302 -49.5% ± 7.0. Zacopride and 
RS67333 are equally ineffective at activating αo producing a negligible response. The EC50 
values for 5-HT, Prucalopride, ML10302, Zacopride and RS67333 are as follows: 185 ± 8.0 
nM, 29.6 ± 9 nM, 1288 ± 12 nM , Zacopride and RS67333 did not significantly differ from 
basal conditions. Using Sidaks multiple comparison tests for the Emax values we established 
the following rank order of efficacies in the activation of αo: 5-HT>Prucalopride≥ML10302. 
There’s a significant difference (p<0.01) between 5-HT and Prucalopride, and an even 
stronger significant difference between 5-HT and ML10302 (p<0.005), but  no significant 
difference between Prucalopride and ML10302. In terms of potency in the activation of αo, 
using Tukey multiple comparison tests of the EC50 results, we establish a rank order of  
Prucalopride> 5-HT >ML10302 (p<0.0001). 
The results for RS67333 and Zacopride are very similar. Both are able to activate the αs G 
protein that is the first step in the cAMP pathway leading to the augmentation of CREB and 
they both inadequately activate αo, which is significant for the inhibition cAMP pathway. 5-
HT, as expected, significantly activates both αo  and αs. ML10302 appears to weakly activate 
αo and not significantly activate αs. Prucalopride acts similarly to 5-HT activating both αs and 
αo but to a lesser extent.   
3. 5-HT4R ligand-induced internalization 
RS67333 when tested in vivo showed no tolerance during short or long treatment.(Vilaró and 
Piñeyro 2010). Tolerance is when a subject’s reaction to a specific drug and concentration of 
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Figure 15 .Dose response of 5-HT4 ligands as measured by a BRET-based conformational 
biosensor monitoring αio/γ2 interaction.  
HEK293 cells are transfected with 0.35 μg of αoi90RlucII, 3 μg of  γ2GFP
10, 3 μg of β1 and 10 μg of HA-5-HT4B 
and exposed agonist for 2 min before taking BRET measurements. (A) The Net BRET signal change of the 
interaction with 5-HT. The complex formed has and increased BRET signal under basal conditions. Results were 
compared by means of unpaired, two tailed Student’s t test with a significant difference of p=0.0491.(B) Results 
represent change with respect to Basal BRET (0.643 ±0.02) and correspond to the mean ± SEM of 10 
independent experiments. Curves were compared by means of 2 way ANOVA which indicated an effect of drug 
of 18.7 % (p<0.0001), a concentration effect of 8.3% (p<0.0001) and an interaction of 19.8% (p<0.0001).  
Posthoc analysis by using Sidak comparison test indicated that RS67333 and zacopride were different from the 
endogenous ligand 5-HT (p<0.0001). The effect of concentration was further analyzed using Dunnett’s test to 
compare the response in the absence of ligand to responses obtained at difference concentrations. Statistical 
significance is shown on graph. 
A 
B 
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Table II. Emax  and EC50 values obtained from dose response curves generated of 5-HT4 
ligands as measured by a BRET through αo/γ2 interaction (figure 15B) 
 
EC50(nM) ± s.e.m. Emax ± s.e.m 
5-HT 185.0 ± 7.9  -0.0308 ±0.002 
Prucalopride 29.6 ± 9.0 -0.0228 ± 0.002 
ML10302 1288 ± 11.5
 
-0.0160 ±0.003 
 
Zacopride N/A
 
N/A
 
RS67333 N/A N/A 
A 1-way anova determined overall significant variation across EC50 for the different ligands with a p<0.0001. 
Post hoc Sidak multiple comparison test allowed us to establish the following rank order: the EC50 value for 
ML10302 was significantly higher than for 5-HT (p<0.0001), that of 5-HT was significantly higher than that of 
Prucalopride (p<0.0001). A 1-way anova determined overall significant variation across Emax for the different 
ligands with a p<0.0001. Post hoc Sidak multiple comparison test allowed us to establish the following rank 
order: the Emax value for 5-HT was significantly higher than for ML10302 (p<0.01), that of prucalopride did not 
significantly differ from ML10302 and 5-HT.  
the drug is reduced followed by repeated use, requiring an increase in concentration to achieve 
the desired effect.  In terms of pharmacodynamics, this could be caused by a reduction of 
receptors that respond to the specific drug or agonist, or receptor desensitization in which the 
ion current through an open channel decreases. A risk of long term exposure to a GPCR 
agonist is desensitization via receptor phosphorylation and endocytosis (Johnson 2006). 
Endocytosis is a form of active transportation by which a cell transports receptors, antibodies, 
molecules   into the cell via pinocytosis or phagocytosis (Silverstein, Steinman et al. 1977).  
Endocytosis can be a part of the process of activation of desensitization of a receptor 
(Whistler, Chuang et al. 1999; Martini and Whistler 2007). We want to look at receptor 
endocytosis in response to RS67333 and compare it to other agonists with the purpose of 
understanding why RS6733 does not produce tolerance (Vilaró and Piñeyro 2010). To address 
this issue, we treated cells with different agonists for a period of 60 min at concentrations 
ranging from 10
-10
 to 10
-4 
M (figure 16). We saw that 5-HT induced the most sequestration of 
the 5-HT-4b receptor which corresponded to the sequestration of 37.5 % ± 2.5% membrane 
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receptors. In order to compare agonists internalization, all other ligands were normalized with 
respect to 5-  
  
Figure 16. Dose response of 5-HT4 receptor ligands induced internalization of 5-HT4b 
receptors as measured by ELISA assay.  
This graph represents internalization of the receptors after 60 min exposure to indicated concentrations of ligand. 
They represent mean ± s.e.m. of 7 experiments and are normalized by attributing the highest concentration used 
of 5-HT (10
-4 
M) as 100%. Curves were compared by means of 2 way ANOVA which indicated an effect of drug 
of 26.1 % (p<0.0001), a concentration effect of 29.6% (p<0.0001) and an interaction of 19.5% (p<0.0001).  
Posthoc analysis by using Sidak comparison test indicated that RS67333 and ML10302 were different from the 
endogenous ligand 5-HT (p<0.0001);  Prucalopride and Zacopride were different from RS67333 and ML10302 
(p<0.01). The effect of concentration was further analyzed using Dunnett’s test to compare the response in the 
absence of ligand to responses obtained at difference concentrations. Statistical significance is shown on graph. 
HT. Hence, 5-HT displayed an Emax of 105.0 ± 4.4, Zacopride of 87.5 ± 7.0, Prucalopride of  
82.6 ± 6.3, RS67333 and ML10302 had negligible internalization.  As can be seen 5-HT, 
Zacopride and Prucalopride  produced  a maximum of 5-HT4b receptor internalization.  While 
RS67333 and ML10302 had negligible internalization. Except for RS67333 all drug profiles in 
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internalization resemble those observed for αo but are quite distinct from those involving αo 
activation. 
 
Table III. Emax and EC50 values obtained from dose response curves generated by 5-HT4 
ligands as measured by ELISA through internalization of 5-HT4B receptors (figure 16)   
 EC50(nM)+ s.e.m Emax (%) + s.e.m. 
5-HT 76.2  ±  5.8 37.5± 2.5 
Zacopride 684 ± 8.1  33.1 ± 3.0 
Prucalopride 651 ± 10.1 28.7 ± 3.1  
RS67333  N/A N/A 
ML10302 N/A N/A 
A 1-way anova determined that there were significant differences between the EC50  results between each ligand 
with a p<0.0001. Values were extracted by curve fitting of the curves in fig 16B. Post hoc Sidak multiple 
comparison test allowed us to establish the following rank order: the EC50 value for Zacopride  was significantly 
higher than for Prucalopride (p<0.05), that of  Prucalopride was significantly higher than that of 5-HT 
(p<0.0001). A 1-way anova determined overall significant variation across Emax for the different ligands with a 
p<0.0001. Post hoc Sidak multiple comparison test allowed us to establish the following rank order: the Emax 
value for 5-HT was significantly higher than for Zacopride (p<0.01), that of Zacopride did not significantly differ 
from Prucalopride.  
4. 5-HT4R ligand profiles 
As can be seen in table IV no two drugs resemble each other in  their signaling profile pointing 
to unprecedented signaling diversity amongst 5-HT4 receptor agonists. ML10302 is a partial 
agonist for Gαo, but not for Gαs and does not induce receptor internalization. RS67333 is a 
partial agonist for Gαs but not for Gαo  and does not induce receptor internalization. 
Prucalopride is a partial agonist for Gαs, Gαo, and induces receptor internalization. Zacopride 
is a partial agonist for Gαs but not Gαo and induces receptor internalization. While 5-HT is a 
full agonist and induces maximal conformational change of the Gαs and Gαo as well as 
inducing maximal receptor internalization.  
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Table IV. The 5-HT4 receptor ligands profiles summarized from results of BRET 
measurements of Gαs and Gαo  as well as internalization experiments by ELISA. 
 ML10302 RS67333 Prucalopride Zacopride 5-HT 
Gαs –* ○ ○ ○ ●*** 
Gαo ○** – ○ – ● 
Internalization – – ○ ○ ● 
5-HT4  receptor profiles of obtained data. 
 * –  = Negligible response, **○ = Partial agonist , ***● = Full Agonist,   – = No response 
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Discussion 
In this study we showed that 7 days of treatment with RS67333 reduced CREB activity in 
ventral striatum of control rats but increased pCREB levels in ventral and dorsal striatum of 
OBX rats.  We then used cultured cells transfected with bioluminescent proteins to compare 
RS67333 to other agonists in their ability to activate Gαs and Gαo proteins (BRET) and induce 
internalization, concluding that 5-HT4 receptor respond to agonists in a ligand-specific 
manner. 
Modulation of striatal CREB activity 
The ability of RS67333 to influence CREB levels was studied in dorsal and ventral striatum in 
control rats and OBX rats. Our interest in RS67333 biochemical response in these structures 
comes from observations that RS673333 has rapid AD effect evidenced by anti-anhedonic 
actions in the OBX model (Lucas, Rymar et al. 2007). The striatum is a key player in reward 
response (Delgado 2007). While the ventral striatum is predominantly involved in emotional 
responses to stimuli (Cardinal, Parkinson et al. 2002).  The dorsal striatum is involved in the 
motor control of the responses (Balleine, Delgado et al. 2007). The phosphorylation state of 
CREB is crucial in the context of evaluating the antidepressant properties (Chen, Shirayama et 
al. 2001). We started by determining how OBX affects the pCREB levels in the striatum,  a 
region that is known to express high levels of 5-HT4Rs and mediates normal hedonic 
responses (Nestler and Carlezon 2006). Anhedonia is one of the central symptoms of 
depression and RS67333 has been shown to reverse this anhedonia in depression-like states 
caused by olfactory bulbectomy (Leonard 1984). Hence, we started by evaluating whether 
OBX changed pCREB within the striatum, a brain structure that is directly involved in 
mediating reward response.  RS67333 administration to control rats reduced pCREB levels in 
ventral striatum leaving dorsal striatum unchanged, suggesting regional differences in 
response to the drug. On the other hand, RS67333 administration for only 3 days significantly 
increased the pCREB/tCREB ratio in striatum of OBX rats whose anhedonic state had been 
successfully treated with RS67333 (Lucas, Rymar et al. 2007).  A possible explanation for 
these observations is that changes in CREB activity may not be involved in promoting 
anhedonic behaviour but could contribute to its reversal during antidepressant response. 
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Response to the RS67333 in OBX rats was observed both in ventral striatum and dorsal 
striatum. The fact that the RS67333 response in ventral striatum resembled that of OBX in 
sham rats and reverted OBX actions in lesioned rats clearly shows a state-dependent effect of 
RS67333. Similarly the RS67333 response in the dorsal striatum was also distinct in sham and 
OBX.  In this case, RS67333 could behave as an agonist, but when 5-HT levels are normal 
RS67333 could compete with the endogenous NTs. A precedent in the literature for this type 
of behaviour is aripiprazole: a partial D2 agonist that in the brain has biphasic effect.  It is an 
agonist when DA levels are low but blocker when DA levels are high. It is an antipsychotic 
drug (Stahl 2001). The only way this explanation could be valid would be if RS67333 were a 
partial agonist. So we compared RS67333 efficacy to induce signalling to the efficacy of other 
agonists. We chose αs and αo because they are the 1
st
 step in the cascade to pCREB. 
G protein activation by 5-HT4R agonists 
The Gαs protein is the first relay point from the 5-HT4R’s to the cAMP signalling pathway 
which is involved in the activation of pCREB though the activation of PKA. Activation of the 
G protein was assessed in vivo in real time by means of a conformational biosensor of trimeric 
G protein activation (Gales, Rebois et al. 2005; Gales, Van Durm et al. 2006; Audet, Gales et 
al. 2008).  Comparing the parameters of the different dose response curves by means of 
simultaneous curve fitting indicated that 5-HT was the most efficacious agonist producing the 
largest maximal effect. Any non-negligible change in delta net BRET, is indicative of a 
conformational change. BRET measures energy transfer; a conformational change resulting in 
the fluorescent proteins being in closer proximity would increase the delta net BRET signal; a 
conformational change  where the fluorescent proteins are moved away from each other or 
blocked by the tertiary structure is also indicative of a conformational change that is 
measureable. Measuring Gαs and Gαo it is not surprising to see that the endogenous 5-HT, has 
the greatest delta net BRET and is a full agonist in both assays. If we take a look at the 
summary table (table IV) we can see that RS67333 behaved as partial agonist in αs activation 
but produced no significant effect with a αo biosensor. This observation is consistent with our 
hypothesis that RS67333 could work to enhance or inhibit the system according to 5-HT 
endogenous levels. If we now compare RS67333 to other ligands taking the endogenous 
ligand 5-HT as standard: all synthetic ligands have partial efficacy in either promoting 
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activation of αs or αi. An interesting observation is that there are not two ligands with similar 
signaling profile. ML10302 has no efficacy to engage αs and has similar Emax as Prucalopride 
in αi. Prucalopride is similarly and partially efficacious in both α signaling pathways. Its 
efficacy is indistinguishable from Zacopride for αs; which in turn displays no efficacy for αi.  
This drug behaviour which shows ligand specific response in different signaling pathways is 
the hallmark of functional selectivity (Kenakin 2011). An interesting observation is that 
RS67333 follows ML10302’s dose response curve for αi activation except for the highest 
concentration. This bizarre behaviour of RS67333 was consistently repeated in each 
experiment as shown by small s.e.m. of this point. A plausible explanation is that at this high 
concentration RS67333 preferentially engages the endogenous αs protein, rather than the αo-
RlucII90γ2GFP
10
 biosensor. In keeping with this reasoning, ML10302 which has no efficacy 
with αs produces a full curve for αo as do 5-HT and prucalopride which both are more 
efficacious than RS67333 in both assays. Among all drugs ML10302 resembles RS67333 in 
its weak signaling responses. If partial agonism is the signaling property that makes RS67333 
an effective AD we would expect ML1032 to have at least some of RS67333’s in vivo 
responses. It is also worth noting that Zacopride and RS67333 activate Gαs similarly and also 
fail to significantly activate Gαo. The differences between these two drugs lies in their abilities 
to cause receptor internalization, since Zacopride activates internalization of the receptor. In 
the case of treatment of depression, it would be undesirable for receptors that produce AD 
effects to be internalized. Zacopride is already available and is used as an anxiolytic; anxiety 
having many parallels, and co-occuring with depression with a high frequency (Rice, van den 
Bree et al. 2004). RS67333 could be the longer lasting version of Zacopride that treats 
prolonged anxious/depressive symptoms. 
5-HT4 receptor agonists effects on 5-HT4 receptor internalization 
Endocytosis is a form of active transport of molecules, particles and receptors from outside the 
cell to inside the cell. When a receptor has a ligand bound that is eliciting an ongoing signal, 
the receptor may be signaled to undergo endocytosis. When this happens G-protein Receptor 
kinases are activated and will phosphorylate the cytosol tail of the receptor. The 
phosphorylation of this tail attracts β arrestins which will start the invagination process of the 
receptor and signal clathrins to start forming clathrin coats. This pocket in the cell membrane 
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requires the protein dynamin to reform and bind the end of the membrane back together to 
form the endosome containing the receptor. This endosome can be recycled back to the cell 
membrane at varying speeds.  
Internalization is an important aspect of receptor tolerance.  When a receptor is continuously 
stimulated it may lead to prolonged desensitization if the receptor is sent for degradation or to 
resensitization if the receptor is recycled to the membrane. Internalization without recycling 
has been associated with analgesic tolerance to delta opioid agonist (Audet, Charfi et al. 
2012). Similarly, lack or poor internalization of μ-opioid receptor by morphine is also 
associated with tolerance due to lack of resensitization (Bohn, Gainetdinov et al. 2000; Groer, 
Schmid et al. 2011).  Given the nature of depression and its chronic condition, a drug that may 
induce tolerance is undesirable. RS67333 and ML10302 displayed no internalization: while 
the other three agonists produced significant sequestration. In the literature daily treatment 
over 21 days of zacopride showed a down-regulation of 5-HT4 receptors in striatum and 
hippocampus.  The most feasible explanation indicates that this down-regulation reflects 
internalization and/or increased degradation as a consequence of prolonged exposure (Vidal, 
Valdizán et al. 2010). In terms for 5-HT4R occupancy, prucalopride was found to bind 
relatively weakly compared to RS67333. A study by Nirogi et al. of rat striatal 5-HT4R 
occupancy found that an intravenous dose of 10mg/kg of RS67333 was necessary for 100% 
occupancy, while prucalopride maximum occupancy was 75% with a dose of 50 mg/kg.  
Plasma concentration of 50 ng/ml of RS67333 was required for 100% occupancy, 
prucalopride reached 75% occupancy when concentration was 5000 ng/ml (Nirogi, Kandikere 
et al. 2013). We observed that RS67333 produced no tolerance after three weeks so in this 
case lack of internalization may contribute to RS67333’s prolonged response. 
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Conclusion 
In summary, we have tested five agonists in a) the main signaling pathway that control CREB 
activity, b) in a regulatory response that leads to tolerance and c) we have assessed the ability 
of RS67333 to modulate CREB activity in relation with its anti-anhedonic effects. The data 
obtained are consistent with the notion that RS67333 stimulates CREB activity via αs 
activation and that it does so with less internalization as compared to agonists of similar 
efficacy to activate αs (eg: Zacopride, Prucalopride). It would now be of interest to pursue the 
question of how this drug resembles and differ with respect to AD effects particularly the 
reversal of OBX-mediated anhedonia. Under this model, the best AD agonist would be region 
and receptor specific. The agonist would not overstimulate the receptor and not block the 
endogenous ligand.  
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